Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Weight Loss in Non-diabetic Obesity
NCT06000462Phase 4Active, not recruiting
- Sponsor
- Oman Ministry of Health
- Start
- Apr 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in obesity, sponsored by Oman Ministry of Health. Started Apr 2024; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06000462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06000462.